Benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them

A method of inhibiting tumor growth or cancerous metastases in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of a compound of the formula

• wherein R1 and R2 are independently hydrogen or alkyl of 1 to 6 carbon atoms, unsubstituted or substituted by R3,
• or R1 and R2 together form a saturated or unsaturated divalent alkylene of 2 to 9 carbon atoms, unsubstituted or substituted by at least one member selected from the group consisting of halogen, (C1-C6) -alkyl, (C1-C6)-alkoxy, (C6-C14)-aryl, (C6-C14)-aryl-(C1-C6)-alkyl, (C5-C14-heteroaryl, (C5-C14-heteroaryl-(C1-C6)-alkyl, (C3-C12)-cycloalkyl, (C3-C12)-cycloalkyl-(C1-C6)-alkyl and oxo, said divalent alkylene able to be attached at the level of the carbon—carbon bond to a carbocycle or a heterocycle with 5 to 7 ring members containing 1 or 2 nitrogen atoms, saturated or unsaturated, unsubstituted or substituted by 1 or 2 R3;
• R3 is selected from the group consisting of (C1-C8)-alkyl, (C1-C8)-alkoxy, (C5-C14)-aryl-(C5-C14-aryl-(C1-C4)-alkyl, halogen, trifluoromethyl, hydroxyl, nitro, amino, NH—((C1-C4)-alkyl, N((C1-C4)-alkyl)2, NHCO—(C1-C4)-alkyl and CO—(C1-C4)-alkyl;
• R4 is selected from the group consisting of hydrogen, (C1-C6)-alkyl-CO—O—(C1-C4)-alkyl and (C1-C6)-alkyl, unsubstituted or substituted by a member selected from the group consisting of hydroxyl, (C1-C4)-alkyl-SO2, NR9RR9, and N+R9R9′R9″Q−, R9, R9′ and R9″ are independently selected from the group consisting of hydrogen, (C1-C6)-alkyl, (C5-C14)-aryl and (C3-C14)-aryl-(C1-C6)-alkyl and Q is a physiologically acceptable anion,
• or R4 is selected from the group consisting of
• the dotted lines representing the position of the bond;
• R5 is selected from the group consisting of hydrogen, —CO2R6—, —SO2—R6, —SO2NHR6, —SO2NHCOR6, —SO2NHCO2R6, —CONH2 and —CONHR6, R6 is selected from the group consisting of (C1-C8)-alkyl, (C6-C14)-aryl, (C6-C14-aryl-(C1-C6)-alkyl, (C5-C14)-heteroaryl, (C5-C14)-heteroaryl-(C1-C6)-alkyl, (C3-C20)-(mono-, bi- or tri-)-cycloalkyl, (C3-C20)-(mono-, bi- or tri-)-cycloalkyl-(C1-C6)alkyl, the aryl or heteroaryl radical being unsubstituted or substituted by 1 to 3 R3;
• R7 is selected from the group consisting of hydrogen, (C1-C6)-alkyl-O—CO—, hydroxyl, (C1-C6)-alkyl-O—CO—O and nitro;
• m is equal to 0, 1, 2 or 3;
• said compounds being in all their possible isomer forms, alone or in a mixture ratio, the acyl guanidine group adjacent to the phenyl being in a para or meta position to the oxygen, and its pharmaceutically acceptable salt sufficient to inhibit tumor growth or cancerous metastases.